Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7058 vs Investigator-Selected KRAS G12C Inhibitor in KRAS G12C-positive Advanced or Metastatic NSCLC
NCT07601048Phase 3Not yet recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jun 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-7058 in non-small cell lung cancer (NSCLC), sponsored by Shandong Suncadia Medicine Co., Ltd.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HRS-7058
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07601048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601048.